Anastasiia Nesova

Dr. Anastasiia Nesova

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ANAnastasiia Nesova
Anastasiia Nesova
DTD. B. Tsydypova
D. B. Tsydypova
VRVyacheslav Ryabov
Vyacheslav Ryabov
Aim. To identify the main clinical and paraclinical characteristics of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) of various risk groups for adverse ischemic events, as well as to describe the in-hospital outcomes of the disease. Material and methods. The retrospective analysis included 600 patients who were hospitalized at the regional vascular center from January 2019 to January 2021 with a diagnosis of NSTE-ACS. Results. Patients were stratified into very high — 208 (34,7%), high — 196 (32,7%), moderate — 108 (18%) and low — 88 (14,6%) risk groups. In the highand very high-risk groups, patients were older, characterized by a significant comorbidity index, increased bleeding risk, decreased left ventricular ejection fraction and glomerular filtration rate in comparison with patients of other groups (p<0,05). Very highrisk patients were characterized by associated clinical conditions, predominantly infectious diseases and decompensated heart failure. Unfavorable outcome of hospitalization was observed in 44 (7,3%) patients. The death probability in the very high-risk group (33; 15,9%) was higher than in the low-risk group (2; 2,3%) (Odds ratio 8,1 (95% confidence interval: 1,9-34,6); p=0,01). Regardless of the risk degree, there was a high (53,5%) likelihood of completing invasive coronary angiography as a diagnostic procedure. Most of the observed complications as a result of invasive coronary angiography were characteristic of the high(18,3%) and very high-risk groups (21,5%). Conclusion. NSTE-ACS patients at very high/high risk of adverse ischemic events represent a heterogeneous group with cardiac and noncardiac pathologies with high comorbidity and bleeding risks, decreased left ventricular ejection fraction and glomerular filtration rate, and associated clinical conditions.

17 April 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ANAnastasiia Nesova
Anastasiia Nesova
VRVyacheslav Ryabov
Vyacheslav Ryabov
The aim of the review was to identify current barriers, "paradoxes", in the treatment of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS), based on a critical analysis of modern studies and identified evidence gaps.NSTE-ACS can be considered from the perspective of the following paradoxes: the risk-treatment paradox; risk stratification paradox; scope and timing of dual antiplatelet therapy; paradox of insufficient benefit of invasive treatment; age and comorbidity; tactics for multi-vessel coronary artery disease.A review of publications indexed in the Pubmed and Russian Science Citation Index (RSCI) databases was carried out. The search depth was 10 years (from 2013 to 2023). The search resulted in 328 studies, of which 45 were used to write the final review.

28 February 2026 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
ANAnastasiia Nesova
Anastasiia Nesova
DVDarya Vorobeva
Darya Vorobeva
VRVyacheslav Ryabov
Vyacheslav Ryabov
Background and objectives: The risk-treatment paradox (RTP) has not been studied in very high-risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). We aimed to describe the cohort of very high-risk NSTE-ACS patients, analyse the impact of RTP on outcomes, and identify subgroups of patients who derive the greatest benefit from immediate invasive coronary angiography (ICA). Methods: This retrospective analysis included 340 patients diagnosed with NSTE-ACS who met at least one of the established criteria for very high risk at admission. RTP was defined as any management tactic other than emergency (<2 h) ICA. Ongoing myocardial ischaemia (OMI) was defined as a combination of ongoing or recurrent chest pain and/or dyspnoea, along with at least one additional established very high-risk criterion. Results: RTP was identified in 213 cases (62.6%). There was no adverse effect of RTP on in-hospital mortality [14% vs. 10% in the RTP group, P = 0.34, odds ratio (OR) 0.708; 95% confidence interval (CI) 0.36–1.37] or on the incidence of long-term major adverse coronary events (MACE). An independent predictor of adverse outcomes was evidence of OMI at hospital admission. Signs of OMI were observed in 168 patients (49.4%). In this subgroup, failure to perform emergency invasive coronary angiography was associated with a higher incidence of MACE during the three-year follow up (29% vs. 47.5% in the RTP group, P=0.02, OR 2.2; 95% CI 1.0–4.5). Interpretations and conclusions: There was no significant effect of risk-treatment paradox on outcomes in very high-risk patients. Patients with signs of ongoing myocardial ischaemia benefit most from undergoing emergency invasive coronary angiography with the intention of performing percutaneous coronary intervention within two hours.

13 November 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
VRVyacheslav Ryabov
Vyacheslav Ryabov
YSYulia Samoylova
Yulia Samoylova
AGAleksandra Gombozhapova
Aleksandra Gombozhapova
ANAnastasiia Nesova
Anastasiia Nesova
IKIrina Kologrivova
Irina Kologrivova
Background. Phenotyping inflammation in ST-elevation myocardial infarction (STEMI) is a challenge for modern cardiology. NLRP3 inflammasome is a proven predictor of adverse outcomes in cardiovascular disease, but its specificity in stratifying inflammatory activity in patients with myocardial infarction (MI) has not been demonstrated. The aim of this paper is to describe the levels of NLRP3 protein and IL-1β concentrations and their changes in dynamics and associations with clinical, laboratory and instrumental characteristics of patients with STEMI. Methods. A total of 45 patients with STEMI were enrolled. Concentrations of NLRP3 and IL-1β were evaluated in arterial and venous EDTA blood from the infarct-related coronary and peripheral arteries and veins on days 1, 3 and 7 after MI. Results and Conclusions. The concentrations of markers were higher on the first day after MI with a maximum decrease on the third day. The levels of both markers in venous plasma correlated with those in arterial blood, allowing their routine determination in venous plasma on the first day after MI. IL-1β levels correlated directly with the wall motion index and inversely with left ventricular ejection fraction and stroke volume, which characterize the potential contribution to adverse myocardial remodeling. There were two multidirectional trends in changes in NLRP3 and IL-1β levels during hospitalization. Initially higher levels with a gradual decrease by day 7 were associated with a longer duration of myocardial ischemia and higher plasma troponin I levels. Further evaluation of the long-term outcomes of MI will allow identifying inflammatory factors that input to the development of secondary major adverse cardiac events and will provide a new step in the understanding of inflammatory phenotyping.

28 February 2025 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
EKElena Kuzheleva
Elena Kuzheleva
AGAlla Garganeeva
Alla Garganeeva
АРАлексей Николаевич Репин
Алексей Николаевич Репин
ANAnastasiia Nesova
Anastasiia Nesova
MKMichail Kondratiev
Michail Kondratiev
МКМихаил Юрьевич Кондратьев
Михаил Юрьевич Кондратьев
HighlightsIn the current epidemiological situation, special attention should be paid to patients suffering from cardiovascular diseases, as they are more susceptible to the severe course of the new coronavirus infection. The study of aspects of treatment adherence and quality of life of cardiac patients plays an important role in providing these patients with qualified care. Aim. Study the quality of life and adherence to treatment of patients who applied for elective cardiac care during the pandemic of a new coronavirus infection.Methods. The study included 310 patients who applied to the cardiological dispensary in March 2021 (n = 123) and in the same period in 2017 (n = 187). To analyze adherence to treatment, the Morisky-Green compliance scale, a modified questionnaire to determine the factors influencing adherence, and the international questionnaire EuroQol EQ5D5L were used. Statistical processing was performed using the STATISTICA 10.0 program.Results. In 2021, the incidence of diagnosed CHF among patients included in the study was three times higher than in 2017 and amounted to 67.2% (p < 0.001). The level of quality of life on the EQ5D5L scale, as well as self-assessment of the health of patients on the VAS scale, were higher in the 2021 cohort of patients (p < 0.05). Approximately half of the patients surveyed do not comply with medical prescriptions, which is in line with the results of 2017. Forgetfulness remains the main reason for non-compliance with medical recommendations.Conclusion. During the COVID-19 pandemic, there has been a threefold increase in the proportion of patients suffering from CHF among the studied cohort of patients. At the same time, the level of quality of life and self-esteem of health is higher during the COVID-19 pandemic. Adherence to treatment of patients during the studied period remains low. During the COVID-19 pandemic, the financial aspect has an important impact on therapy adherence. A negative correlation was established between the presence of psychoemotional disorders and the degree of adherence to treatment. This actualizes the need to identify patients with symptoms of anxiety/depression among cardiac patients and provide them with specialized psychological assistance.

22 March 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
ANAnastasiia Nesova
Anastasiia Nesova
DVDarya Alexeevna Vorobeva
Darya Alexeevna Vorobeva
VRVyacheslav Ryabov
Vyacheslav Ryabov
There is reason to believe that unfavorable outcomes of non-ST-elevation acute coronary syndrome (NSTE-ACS) is due to the “risk-treatment” paradox (RTP). However, the true prevalence, types and causes of RTP have not been studied, and data from previous studies have shown an equivocal effect of RTP on outcomes of NSTE-ACS. The retrospective analysis included 600 patients initially diagnosed with NSTE-ACS. Upon admission, all patients were re-stratified into four groups according to their risk of adverse ischemic events. RTP was defined as a mismatch between a patient’s risk profile and the recommended invasive strategy. RTP was present in 53.5% of the study population (321/600), with the highest frequency observed in the intermediate-risk group (74%) and the lowest in the high-risk group (28.5%). In the overall cohort, the presence of RTP (n = 321) was not associated with a significant difference in in-hospital adverse cardiovascular events or length of stay compared to patients without RTP (n = 279). After adjustment for RTP in each risk group, only the high-risk group showed an increase in adverse outcomes in the presence of RTP (5.4% mortality vs. 2.9% (OR 1.9 (95% CI 0.5–8.9), p = 0.037) and a negative effect of RTP on the risk of recurrent myocardial ischemia (RMI) after 24 h (7.1% vs. 0.7%, OR 10.7 (95% CI 1.2–97.9), p = 0.01). RTP in relation to the type of invasive strategy is common in patients with NSTE-ACS (53.5%). For high-risk patients, RTP worsened in-hospital outcome and influenced the risk of RMI after 24 h. This research is a retrospective observational study, which does not require mandatory registration as defined by the ICMJE. The evidence base for invasive management strategies in NSTE-ACS is not perfect; Objective risk stratification is not fully implemented in practice; The “risk-treatment” paradox is typical for 53.5% of NSTE-ACS patients; The “risk-treatment” paradox worsens hospital outcomes only in high-risk patients.